Literature DB >> 21906809

Gain-of-function of P2X7 receptor gene variants in multiple sclerosis.

Olatz Oyanguren-Desez1, Alfredo Rodríguez-Antigüedad, Pablo Villoslada, María Domercq, Elena Alberdi, Carlos Matute.   

Abstract

We have previously shown that P2X7 receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates chronic experimental autoimmune encephalomyelitis. Here, we have explored the putative association of functionally relevant single nucleotide polymorphisms of the P2X7 receptor gene with multiple sclerosis. We found that T allele of rs17525809 polymorphism, which yields an Ala-76 to Val change in the extracellular domain, is more frequent in multiple sclerosis patients than in controls. Importantly, P2X7 variants with Val show a gain-of-function consisting in higher calcium permeability, larger electrophysiological responses and higher ethidium uptake, and enhance the effect of the also gain-of-function His-155 to Tyr substitution (rs208294) in the haplotype formed by these two variants. These findings may contribute to define the genetic background predisposing for multiple sclerosis and its pathophysiology.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906809     DOI: 10.1016/j.ceca.2011.08.002

Source DB:  PubMed          Journal:  Cell Calcium        ISSN: 0143-4160            Impact factor:   6.817


  26 in total

1.  Polymorphisms in CAMKK2 may predict sensory neuropathy in African HIV patients.

Authors:  Hayley Goullee; Antonia L Wadley; Catherine L Cherry; Richard J N Allcock; Michael Black; Peter R Kamerman; Patricia Price
Journal:  J Neurovirol       Date:  2016-01-19       Impact factor: 2.643

Review 2.  Looking in the Porphyromonas gingivalis cabinet of curiosities: the microbium, the host and cancer association.

Authors:  K R Atanasova; O Yilmaz
Journal:  Mol Oral Microbiol       Date:  2014-02-08       Impact factor: 3.563

3.  Investigation into the association between P2RX7 gene polymorphisms and susceptibility to primary gout and hyperuricemia in a Chinese Han male population.

Authors:  Ying Ying; Yong Chen; Zhen Li; Haiyan Huang; Qiongyao Gong
Journal:  Rheumatol Int       Date:  2017-02-27       Impact factor: 2.631

Review 4.  Purinergic signaling in oligodendrocyte development and function.

Authors:  Taylor G Welsh; Sarah Kucenas
Journal:  J Neurochem       Date:  2018-03-25       Impact factor: 5.372

Review 5.  The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunology       Date:  2013-05       Impact factor: 7.397

Review 6.  From autoinflammation to autoimmunity: old and recent findings.

Authors:  Francesco Caso; Luisa Costa; Valeria Nucera; Giuseppe Barilaro; Ignazio Francesco Masala; Rossella Talotta; Paolo Caso; Raffaele Scarpa; Piercarlo Sarzi-Puttini; Fabiola Atzeni
Journal:  Clin Rheumatol       Date:  2018-07-16       Impact factor: 2.980

7.  Contribution of pannexin1 to experimental autoimmune encephalomyelitis.

Authors:  Sarah E Lutz; Estibaliz González-Fernández; Juan Carlos Chara Ventura; Alberto Pérez-Samartín; Leonid Tarassishin; Hiromitsu Negoro; Naman K Patel; Sylvia O Suadicani; Sunhee C Lee; Carlos Matute; Eliana Scemes
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

8.  Neurotransmitter signaling in the pathophysiology of microglia.

Authors:  María Domercq; Nuria Vázquez-Villoldo; Carlos Matute
Journal:  Front Cell Neurosci       Date:  2013-04-19       Impact factor: 5.505

9.  NLRP3 Inflammasome and MS/EAE.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Autoimmune Dis       Date:  2013-01-08

10.  Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms.

Authors:  Lin-Hua Jiang; Jocelyn M Baldwin; Sebastien Roger; Stephen A Baldwin
Journal:  Front Pharmacol       Date:  2013-05-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.